Engineered immune cells take on Hard-to-Treat blood cancer

NCT ID NCT03758417

Terminated Disease control Sponsor: Nanjing Legend Biotech Co. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new treatment called LCAR-B38M CAR-T cells in 123 Chinese adults with multiple myeloma that had returned or not responded to at least three prior therapies. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. The main goal was to see how many patients achieved at least a partial response, while also monitoring side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Fujian Medical University Union hospital

Fuzhou, Fujian, 350001, China
Jiangsu Province Hospital

Nanjing, Jiangsu, 210029, China
Nanjing Drum Tower Hospital

Nanjing, Jiangsu, 210008, China
Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China
Ruijin Hospital, Shanghai Jiao Tong University

Shanghai, Shanghai Municipality, 200025, China
Shanghai Changzheng Hospital

Shanghai, Shanghai Municipality, 200003, China
Shanghai Fourth People Hospital

Shanghai, Shanghai Municipality, 200434, China
Sun Yat -Sen University Cancer Center

Guandong, Guangzhou, 510060, China
The First Affiliated Hospital, Medical School of Zhejiang University

Hangzhou, Zhejiang, 310003, China
The Second Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, 710004, China
West China Hospital, Sichuan University

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.